Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Fennec Pharmaceuticals ( (TSE:FRX) ).
Fennec Pharmaceuticals reported new real-world data indicating that PEDMARK can be safely administered at least six hours after cisplatin in adults with head and neck cancers and integrated smoothly into routine care without disrupting curative treatment. The findings, presented at a major head and neck cancer symposium, suggest early signals of hearing preservation even in high-risk patients with pre-existing impairment, with good tolerability and no severe toxicities observed.
The company argues these results demonstrate the feasibility and scalability of PEDMARK use beyond its current pediatric indication, potentially supporting broader clinical adoption in a sizable adult population vulnerable to permanent cisplatin-induced hearing loss. Given the high incidence and long-term impact of ototoxicity among cancer survivors, the data could strengthen Fennec’s positioning in survivorship-focused oncology care and expand the market opportunity for PEDMARK if further studies confirm these benefits.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on TSE:FRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.
The score is primarily held back by mixed financial performance (TTM losses, renewed cash burn, and weak capitalization in the provided statements) and bearish technical signals (below key moving averages with negative MACD). Positive corporate events provide an offset through improved commercial momentum and clinical/financing progress, but not enough to outweigh the current financial and trend risks.
To see Spark’s full report on TSE:FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies to prevent chemotherapy-induced toxicities, particularly cisplatin-related hearing loss. Its lead product, PEDMARK (sodium thiosulfate injection), is approved for pediatric patients with localized, non-metastatic solid tumors and holds a 2A recommendation from the National Comprehensive Cancer Network for adolescent and young adult use.
Average Trading Volume: 818
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$425M
See more data about FRX stock on TipRanks’ Stock Analysis page.